Drugs / veldoreotide
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02217839 | Apr 2012 → Jan 2013 | — | Aspireo Pharmaceuticals Limited | Completed | No outcome recorded |
| Phase 1 | NCT02217488 | May → Sep 2008 | — | Aspireo Pharmaceuticals Limited | Completed | No outcome recorded |
| Phase 1 | NCT02217826 | ? → Apr 2014 | — | Aspireo Pharmaceuticals Limited | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02217800 | Nov 2013 → Mar 2014 | acromegaly | Aspireo Pharmaceuticals Limited | Completed | No outcome recorded |
| Phase 2 | NCT02235987 | Oct → Dec 2012 | acromegaly | Aspireo Pharmaceuticals Limited | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04138342 Comparator | Sep 2019 → Jun 2021 | breast cancer, skin cancer | Al-Azhar University | Unknown | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | veldoreotide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04138342 ↗ |
| Known as | COR-005 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989911 ↗ |
| Known as | DG3173 | “Interventions: octreotide and DG3173.” NCT02235987 ↗ |
| Known as | PTR 3173 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989911 ↗ |
| Known as | Somatoprim | “three different doses of Somatoprim (DG3173)” NCT02217826 ↗ |
| Known as | VELD | “somatostatin analog (veldoreotide) (VELD) may be suitable for delivering anti-cancer drugs to target and bioimaging the cancer cells.” NCT04138342 ↗ |
| Known as | Veldoreotida | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989911 ↗ |
| Action | Activate | “VELD as SSTR agonist with anti-cancer activity” NCT04138342 ↗3“Somatostatin receptor 5 agonist” CHEMBL3989911 ↗ “Somatostatin receptor 2 agonist” CHEMBL3989911 ↗ “Somatostatin receptor 4 agonist” CHEMBL3989911 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL3989911 ↗ |
| Route | Subcutaneous | “via single dose subcutaneous injection” NCT02217488 ↗ |
| Target | SSTR2 | “Somatostatin receptor 2 agonist” CHEMBL3989911 ↗ |
| Target | SSTR4 | “Somatostatin receptor 4 agonist” CHEMBL3989911 ↗ |
| Target | SSTR5 | “Somatostatin receptor 5 agonist” CHEMBL3989911 ↗ |